Kadmon Corporation
Delisted (Nasdaq: KDMN): acquired by Sanofi, completed 2021-11-09
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | Rho-associated kinase (ROCK, pan)Small molecule | Graft-versus-Host Disease Chronic Graft-versus-Host Disease |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
2028 (2)
Financial reports
No financial reports recorded.